semaglutide and bone loss GLP-1 drugs — including Ozempic Wegovy — may be tied to a slightly higher risk of osteoporosis and gout, according to research presented at the American Academy of Orthopaedic Surgeons' annual meeting Recent studies involving nearly 150,000

Yes, these medications are approved for weight loss in individuals without diabetes

you are investing in a delivery system that respects your body's biology

In a large cohort of patients across the Cleveland Clinic Enterprise, we found no increase in recurrent pancreatitis among patients who continued GLP-1 RA medication after an episode of acute pancreatitis

Additionally, they found that bone marrow-derived monocytes from bleomycin-treated mice exhibit enhanced migration in vitro compared to control mouse monocytes and that in vivo treatment of the mice with all three CSD subregions reversed this enhanced migration

Regarding approved uses, tesofensine is specifically used to treat obesity, while semaglutide is indicated for both type 2 diabetes and obesity management